We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sony to Accelerate POC Diagnostic Product Development Through Micronics Acquisition

By LabMedica International staff writers
Posted on 10 Oct 2011
Sony Corp. More...
(Tokyo, Japan) has acquired venture corporation Micronics, Inc. (Redmond, Washingtont) through its wholly owned subsidiary, US-based Sony Corporation of America (SCA; New York, NY, USA).

Micronics will be a wholly owned subsidiary of SCA, and will work with the relevant division, including Sony's life sciences R & D team, to develop jointly technologies and new products. The company will continue to operate in Redmond under the current Micronics management team, headed by company President Karen Hedine.

Engaged in the research and development of near patient Point of Care (POC) devices for disease diagnosis, treatment monitoring, and blood testing, Micronics also provides comprehensive product development for third-party clients. The company's main focus in recent years has been its molecular diagnostic platform for the diagnosis of infectious disease.

Mr. Keiji Kimura, EVP and Executive Officer, Sony Corporation, commented, "For some time, Sony has applied its consumer electronics technology to contribute to research and development in the medical and healthcare fields. We believe that the combination of Micronics' development capabilities in the medical diagnosis domain and our consumer electronics and IT technologies, such as in optical discs, will enable us to offer innovative solutions that are responsive to the rapidly escalating needs for Point of Care diagnosis worldwide."

Related Links:
Sony Corp.
Sony Corporation of America
Micronics, Inc.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.